Karyopharm Therapeutics
Emily Rindos is a seasoned professional with extensive experience in quality management systems and technical writing. Currently serving as the Associate Director of Quality Management Systems at Karyopharm Therapeutics Inc. since October 2016, Emily provides strategic and operational leadership to ensure high-quality standards in GCP, GLP, and GMP operations. Previous roles include Manager and Lead positions in QMS Documentation at Zafgen, Inc., where responsibilities encompassed writing standard operating procedures and managing document workflows. Emily also held the position of Assistant Director and Technical Writer at the Center for Invasive Species Management, focusing on technical documentation and grant acquisition, and worked as an Outreach and Science Communication Associate at the Center for Invasive Plant Management. Emily is an alumnus of the University of Montana and Shattuck-St. Mary's School.
This person is not in any teams
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).